Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [21] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Ryan Ashkar
    Darren R. Feldman
    Nabil Adra
    Mohammad Abu Zaid
    Samuel A. Funt
    Sandra K. Althouse
    Susan M. Perkins
    Christin I. Snow
    Kayla M. Lazzara
    Lina M. Sego
    David I. Quinn
    Nasser H. Hanna
    Lawrence H. Einhorn
    Costantine Albany
    Investigational New Drugs, 2021, 39 : 1656 - 1663
  • [22] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Ashkar, Ryan
    Feldman, Darren R.
    Adra, Nabil
    Zaid, Mohammad Abu
    Funt, Samuel A.
    Althouse, Sandra K.
    Perkins, Susan M.
    Snow, Christin I.
    Lazzara, Kayla M.
    Sego, Lina M.
    Quinn, David I.
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    Albany, Costantine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1656 - 1663
  • [23] Cisplatin-refractory germ cell tumours-molecular background and clinical concepts
    Bokemeyer, Carsten
    Skowron, Margaretha A.
    Peters, Mia-Carlotta
    Nettersheim, Daniel
    Oing, Christoph
    ONKOLOGE, 2021, 27 (01): : 46 - 53
  • [24] Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors
    Kawahara, Takashi
    Kawai, Koji
    Kojima, Takahiro
    Nagumo, Yoshiyuki
    Sakka, Shotarou
    Kandori, Shuya
    Negoro, Hiromitsu
    Mathis, Bryan J.
    Maruo, Kazushi
    Miura, Koji
    Sakamoto, Noriaki
    Shinohara, Nobuo
    Yamashita, Shinichi
    Yonemori, Kan
    Kishida, Takeshi
    Ukimura, Osamu
    Nishimura, Kazuo
    Kobayashi, Yasuyuki
    Nishiyama, Hiroyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (07) : 741 - 747
  • [25] Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors:: a study of the German Testicular Cancer Study Group
    Bokemeyer, C.
    Oechsle, K.
    Honecker, F.
    Mayer, F.
    Hartmann, J. T.
    Waller, C. F.
    Boehlke, I.
    Kollmannsberger, C.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 448 - 453
  • [26] Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial
    Tas, F
    Argon, A
    Camlica, H
    Topuz, E
    MELANOMA RESEARCH, 2005, 15 (06) : 543 - 548
  • [27] Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors
    Takumi Shiraishi
    Terukazu Nakamura
    Kazuya Mikami
    Natsuki Takaha
    Akihiro Kawauchi
    Tsuneharu Miki
    International Journal of Clinical Oncology, 2009, 14 : 436 - 441
  • [28] Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors
    Shiraishi, Takumi
    Nakamura, Terukazu
    Mikami, Kazuya
    Takaha, Natsuki
    Kawauchi, Akihiro
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 436 - 441
  • [29] Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors
    Oechsle, Karin
    Kollmannsberger, Christian
    Honecker, Friedemann
    Mayer, Frank
    Waller, Cornelius F.
    Hartmann, Joerg T.
    Boehlke, Ina
    Bokemeyer, Carsten
    EUROPEAN UROLOGY, 2011, 60 (04) : 850 - 855
  • [30] Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors
    Pedro Pérez Segura
    Miguel Gil
    Carmen Balañá
    Ignacio Chacón
    José Muñoz Langa
    María Martín
    Jordi Bruna
    Journal of Neuro-Oncology, 2012, 109 : 137 - 142
12345